Select “appropriate” hemostatic therapy for patients presenting with acute, life-threatening hemorrhage associated with oral anticoagulation
Identify options and limitations for appropriate hemostatic therapy for patients requiring emergent surgery while on factor Xa inhibitors based on different patient specific and surgery specific factors
Develop clinical pathways for efficient use of hemostatic agents in the setting of anticoagulation reversal based on bleed location and severity as well as laboratory parameters
There are multiple controversial topics in anticoagulation reversal without clear data supporting the best approach. These topics include fixed dose vs package insert dosing of prothrombin complex concentrates (PCC) for warfarin reversal, the choice of reversal (andexanet alfa) or replacement product (PCC) for oral Xa inhibitor reversal especially in the setting of urgent/emergent surgery and the role of laboratory monitoring and differentiation of clinical characteristics (bleed size and location) to drive institution prescribing guidelines and reversal order sets.
This presentation will outline the data available on these topics and review the strengths and limitations associated with the different options. The presentation style will include a dialogue with a hematologist and pharmacist at a large academic medical center in Boston, MA and will bring into the conversation typical cases and discussions with front line providers that will make this topic very relatable to other providers who manage these complicated patient cases.
This is an accredited, livestreamed course offered by Harvard Medical School as part of the Contemporary Pharmacotherapy: Collaborative Clinical Explorations series. This course is targeted to pharmacists, pharmacy residents, physicians, physician assistants, clinicians, medical residents, nurses and nurse practitioners.
Select the Take Course button to view additional information on the course registration page.
Contact ceprograms@hms.harvard.edu with questions.
